On October 14, 2021 MiNK Therapeutics, Inc. ("MiNK"), a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, reported the pricing of its initial public offering of 3,333,334 shares of common stock at a public offering price of $12.00 per share (Press release, MiNK Therapeutics, OCT 14, 2021, View Source [SID1234591396]). The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by MiNK, are expected to be approximately $40 million. The shares are expected to begin trading on the Nasdaq Global Market on October 15, 2021 under the ticker symbol "INKT." The offering is expected to close on or about October 19, 2021, subject to the satisfaction of customary closing conditions. In addition, MiNK has granted the underwriters a 30-day option to purchase up to an additional 500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by MiNK.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evercore ISI and William Blair are acting as joint book-running managers for the offering. B. Riley and Baird are acting as co-managers for the offering.

A registration statement relating to the offering of these securities has been filed with the U.S. Securities and Exchange Commission and became effective on October 14, 2021. The offering is being made only by means of a prospectus, copies of which may be obtained from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at (888) 474-0200, or by email at [email protected] and William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, or by telephone at (800) 621-0687, or by email at [email protected]. Copies of the final prospectus, when available, related to the offering will be available at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On October 14, 2021 IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, reported that it has entered into an At-The-Market Distribution Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC, as sole sales agent (the "Agent") (Press release, ImmunoPrecise Antibodies, OCT 14, 2021, View Source [SID1234591227]). Under the ATM Agreement, the Company will be entitled, at its discretion and from time-to-time during the term of the ATM Agreement, to sell, through the Agent common shares of the Company (the "Common Shares") having an aggregate gross sales price of up to US$50 million (the "Offering" or "ATM Facility"). Sales of the Common Shares will be made in transactions that are deemed to be "at-the-market offerings" as defined in Rule 415 of the United States Securities Act of 1933, as amended, and "at-the-market distributions" as defined in National Instrument 44-102 – Shelf Distributions, including, without limitation, sales made directly on the Nasdaq Global Market or any other existing trading market for the Common Shares in the United States. No offers or sales of Common Shares will be made in Canada on the TSX Venture Exchange (the "TSXV") or other trading markets in Canada.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will determine, at its sole discretion, the date, minimum price and maximum number of Common Shares to be sold under the ATM Facility. The Common Shares will be distributed from time to time in negotiated transactions, at market prices prevailing at the time of sale, at prices relating to such prevailing market prices, and/or in any other manner permitted by applicable law. As such, the prices may vary between purchasers over time. The Company is not required to sell any Common Shares at any time during the term of the ATM Facility.

The Company intends to use the net proceeds of the Offering, if any and at the discretion of the Company, to support the growth and development of the Company’s existing operations as well as working capital and general corporate purposes. The Company will pay the Agent a cash fee for Common Shares sold under the ATM Agreement and will reimburse certain expenses incurred by the Agent.

The Company intends to use the net proceeds of the Offering, if any and at the discretion of the Company, to support the growth and development of the Company’s existing operations as well as working capital and general corporate purposes. The Company will pay the Agent a cash fee for Common Shares sold under the ATM Agreement and will reimburse certain expenses incurred by the Agent.

The TSXV has conditionally approved the listing of the Common Shares distributed in the Offering, and the Nasdaq Global Market has been notified of the Offering.

The Offering will be made by way of a prospectus supplement dated October 13, 2021 (the "Prospectus Supplement") to the Company’s existing Canadian short form base shelf prospectus dated December 11, 2020 (the "Base Shelf Prospectus") and U.S. registration statement on Form F-10, as amended (File No. 333-249957), dated January 5, 2021 (the "Registration Statement"). The Registration Statement was declared effective by the United States Securities and Exchange Commission (the "SEC") on January 11, 2021. The Prospectus Supplement has been filed with the British Columbia Securities Commission and the SEC. The ATM Agreement, the Prospectus Supplement and the related Base Shelf Prospectus are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Alternatively, the Agent will send the documents upon request by contacting the Agent: H.C. Wainwright & Co., LLC, 430 Park Avenue 3rd Floor, New York, NY 10022, telephone: (646) 975-6996, email: [email protected]. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

On October 14, 2021 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that it will release its third quarter 2021 financial results on Thursday, October 28, 2021 (Press release, Insmed, OCT 14, 2021, View Source [SID1234591262]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, October 28, 2021 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (844) 200-6205 (U.S. toll free), (646) 904-5544 (U.S. local), or +44-208-0682-558 (international) and referencing access code 594997. The call will also be webcast live on the company’s website at www.insmed.com.

A replay of the conference call will be accessible approximately 1 hour after its completion through November 26, 2021 by dialing (866) 813-9403 (U.S. toll free), (929) 458-6194 (U.S. local), or +44-204-525-0658 (international) and referencing access code 963633. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company’s website at www.insmed.com.

On October 14, 2021 Biotechnology company Tentarix Biotherapeutics LP reported a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital (Press release, Tentarix Biotherapeutics, OCT 14, 2021, View Source [SID1234591228]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The advent of technologies to produce high-precision biologics to engage multiple disease targets represents a major advance," said President and CEO Paul Grayson, a Venture Partner at Versant Ventures. "This financing allows us to develop multiple programs for oncology and autoimmune disease based on the Tentarix technology platform."

A novel platform for generating multifunctional biotherapeutics

Tentarix’s platform creates next generation antibody-based multifunctional biotherapeutics that achieve unprecedented specificity and unique activity. Such products can conditionally activate or inhibit specific cell populations, for example, only activating immune cells that kill cancer cells without activating other immune cells that may create adverse effects.

Previously, the field of multifunctional biotherapeutics has been largely limited to engaging only two targets and has predominantly focused on a few areas of biology, such as T cell engagers. These limitations are due to challenges in discovering molecules that have the desired pharmacology, functional activity, and manufacturability.

Tentarix overcomes these historical challenges. The company’s proprietary platform facilitates high throughput discovery and optimization of biotherapeutics with high cell selectivity, differentiated functionality, and robust mammalian expression that enables molecular developability. The company has already generated proof of concept data in multiple receptor classes.

"It is gratifying to see the vision of multifunctional protein therapeutics shared with the Tentarix founders rapidly develop into a transformative discovery and development company," said Srini Akkaraju, M.D., Ph.D., Managing General Partner at Samsara and Tentarix Chairman. "We believe this powerful platform has broad potential to create differentiated, conditional biotherapeutics across multiple therapeutic areas and with a range of unique and important functionalities."

Lead Programs

The lead program is a multifunctional therapeutic with one subunit that targets the IL2R gamma receptor, a subunit that targets the IL2R beta receptor and other subunits that bind to cell surface proteins on a specific subset of T cells. Potent activity only occurs when all targets are engaged simultaneously to direct powerful biology to this important subset of cells.

Tentarix is advancing programs in many other fields including cell type specific reprogramming and cell population specific delivery and internalization.

"The ability to screen millions of multifunctional molecules for activity and conditionality is a breakthrough," said Jerel Davis, Ph.D., Managing Director at Versant and Tentarix board member. "We believe the team and technology assembled at Tentarix will enable a pipeline of first-in-class biologics with unique function."

Founding Team

Tentarix is led by a seasoned executive team with decades of experience in discovering and developing biologics. More than 30 individuals that include experts in protein engineering, cell surface proteomics, and discovery technology have been assembled in San Diego, California and Vancouver, British Columbia.

Paul Grayson, President, CEO, is a seasoned platform company creator and a Venture Partner at Versant. His experiences include founding roles at Aurora Biosciences (acquired by Vertex), Senomyx (acquired by Firmench), Fate Therapeutics (NASDAQ:FATE) and Bird Rock Bio.
Stephen Demarest, Chief Scientific Officer, was head of Eli Lilly’s Protein Engineering and Computational Biotherapeutics Departments.
Margaret Karow, Chief Development Officer, was Senior Vice President of Preclinical Development for Xilio, Executive Director at Amgen and Vice President at Regeneron.
Paul Kang, Senior Vice President of Corporate Development, was involved in the development and application of antibody generation technologies at ImmGenics, Abgenix, Amgen and Innovative Targeting Solutions.
Alyssa Levin, Chief Financial Officer, was the chief financial officer of Bird Rock Bio and in healthcare finance with PricewaterhouseCoopers LLP.
In addition to Paul Grayson, Paul Kang, Drs. Akkaraju and Davis, Tentarix’s board includes Dr. Marcos Milla, Venture Partner at Samsara BioCapital and former Chief Scientific Officer of Synthorx Inc., acquired by Sanofi.

On October 14, 2021 4SC AG (4SC, FSE Prime Standard: VSC) reported that it will attend and present at the European Organisation for Research and Treatment of Cancer Conference (EORTC) Cutaneous Lymphoma Group 20-21 Meeting in Marseille, France, from 14-16 Oct 2021 (Press release, 4SC, OCT 14, 2021, View Source [SID1234591244]). The posters will be available on 4SC’s website after the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A summary of the posters is listed below.

Poster – RESMAIN study update: RESMAIN study – Evaluating resminostat for maintenance treatment of patients with advanced stage (Stage IIB‑IVB) mycosis fungoides (MF) or Sézarysyndrome (SS)
Poster – Scientific data from research exploring the mode-of-action of resminostat: Mode-of-action of HDAC inhibitor resminostat in CTCL cells